CL2019001310A1 - Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment. (divisional application n ° 01238-2016) - Google Patents
Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment. (divisional application n ° 01238-2016)Info
- Publication number
- CL2019001310A1 CL2019001310A1 CL2019001310A CL2019001310A CL2019001310A1 CL 2019001310 A1 CL2019001310 A1 CL 2019001310A1 CL 2019001310 A CL2019001310 A CL 2019001310A CL 2019001310 A CL2019001310 A CL 2019001310A CL 2019001310 A1 CL2019001310 A1 CL 2019001310A1
- Authority
- CL
- Chile
- Prior art keywords
- fragment
- fusion
- putative partial
- protein
- putative
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Fragmento de la proteína Gc de fusión del género Hantaviru, que consiste de la secuencia de del dominio III parcial putativo de Gc, o de la región troncal parcial putativa de Gc; donde dicho fragmento inhibe la fusión de dicho virus con una célula eucarionte. Composición farmacéutica, que comprende a dicho fragmento y procedimiento de preparación del dicho fragmento de la proteína Gc de fusión del género Hantavirus.Fragment of the fusion Gc protein of the genus Hantaviru, which consists of the sequence of the putative partial domain III of Gc, or the putative partial trunk region of Gc; wherein said fragment inhibits the fusion of said virus with a eukaryotic cell. Pharmaceutical composition, comprising said fragment and method of preparing said fragment of the fusion Gc protein of the genus Hantavirus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2019001310A CL2019001310A1 (en) | 2019-05-14 | 2019-05-14 | Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment. (divisional application n ° 01238-2016) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2019001310A CL2019001310A1 (en) | 2019-05-14 | 2019-05-14 | Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment. (divisional application n ° 01238-2016) |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001310A1 true CL2019001310A1 (en) | 2019-07-05 |
Family
ID=67440476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001310A CL2019001310A1 (en) | 2019-05-14 | 2019-05-14 | Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment. (divisional application n ° 01238-2016) |
Country Status (1)
Country | Link |
---|---|
CL (1) | CL2019001310A1 (en) |
-
2019
- 2019-05-14 CL CL2019001310A patent/CL2019001310A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020016559A2 (en) | Antibodies that target hiv gp120 and methods of use | |
CO2019002556A2 (en) | Pharmaceutical composition | |
MX2020013169A (en) | Camptothecin conjugates. | |
CL2017001920A1 (en) | Human antibodies against Ebola virus glycoprotein | |
ECSP18096095A (en) | ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM | |
UY36304A (en) | FUSION PROTEINS, RECOMBINANT BACTERIA AND METHODS OF USE OF THE RECOMBINANT BACTERIA | |
BR112019000693A2 (en) | mucocharge compositions and methods for use | |
AR108468A1 (en) | CD40L-Fc FUSION POLIPEPTIDES AND THE SAME USE METHODS | |
CL2016002794A1 (en) | Peptide vaccine comprising a mutant ras peptide and a chemotherapeutic agent | |
BR112017016897A2 (en) | fungal strains and methods of use | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
CO2020013833A2 (en) | Anti-programmed death antibody-ligand 1 and its use | |
UY37977A (en) | NEW COMBINATIONS OF DEFLOLIANTS | |
CO2021010786A2 (en) | Inactivated apxia, apxiia, and apxiiia toxins | |
DOP2024000040A (en) | HBV VACCINES AND HBV TREATMENT METHODS | |
MX2020004561A (en) | Bispecific antibodies binding alk-1 and bmpr-2. | |
CL2020000734A1 (en) | Expansion and use of enlarged nk cell fractions. | |
DOP2017000246A (en) | POLIPEPTIDES DIRECTED TO HIV FUSION | |
CO2020007601A2 (en) | Modified brucella vaccine strain for the treatment of brucellosis | |
CU20210008A7 (en) | SOLUBILIZED ASPIRASES | |
CO2019011300A2 (en) | Composition of infliximab containing the histidine buffer system | |
BR112018072699A2 (en) | certain protein kinase inhibitors | |
CL2020002294A1 (en) | Use of an anti-p-selectin antibody | |
CL2021000107A1 (en) | Methods of treating hfpef using dapagliflozin and compositions comprising the same | |
CL2019001310A1 (en) | Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment. (divisional application n ° 01238-2016) |